作者: 燦爛 時(shí)間: 2025-3-21 23:42
https://doi.org/10.1007/978-90-481-8704-1ave a more varied presentation. Bone pain and the signs and symptoms of mediastinal and central nervous system involvement are of particular relevance. Time to presentation for medical attention is related to presenting symptoms. In this chapter, the clinical and laboratory features of ALL at presen作者: 喊叫 時(shí)間: 2025-3-22 01:19 作者: 諷刺 時(shí)間: 2025-3-22 07:37 作者: 獨(dú)行者 時(shí)間: 2025-3-22 11:14
HwanSuk Chris Choi,Ercan Sirakaya Turkple effector mechanisms of the antileukemic agents that are responsible for the efficacy (Fig. 5.1 and Table 5.1). This contrasts the modern era of targeted therapy, where molecular mapping of chemoresistant cancer cells has led to development of drugs that specifically target aberrant pathways (see作者: 江湖騙子 時(shí)間: 2025-3-22 15:20
Filippo M. Denaro,Giuliano De Stefano. MRD measurements have proven to be the strongest independent prognostic factor, allowing for risk-group assignment into different treatment arms, ranging from treatment reduction or intensification. MRD measurements are also guiding treatment decisions in relapsed ALL patients and patients undergo作者: 江湖騙子 時(shí)間: 2025-3-22 18:58 作者: ERUPT 時(shí)間: 2025-3-22 23:36
Katherine N. Marenco,David J. Bottjergic subsets of childhood ALL and improved clinical risk stratification of patients. These genomic advances have further identified key leukaemia-associated pathways and somatic alterations that may be amenable to therapeutic targeting with kinase inhibitors and other molecularly-targeted agents. Thi作者: 琺瑯 時(shí)間: 2025-3-23 04:09 作者: neutrophils 時(shí)間: 2025-3-23 09:03 作者: 公理 時(shí)間: 2025-3-23 11:41 作者: uveitis 時(shí)間: 2025-3-23 16:30
https://doi.org/10.1007/978-94-007-2339-9oved outcomes and 90% of children with newly diagnosed with ALL are now expected to become long-term survivors [1–3]. Concurrently, the burden of intensified therapeutic regimens has become evident; treatment-related toxicity (TRT) not only leads to long-term morbidity and late effects in survivors 作者: DEFER 時(shí)間: 2025-3-23 18:15 作者: justify 時(shí)間: 2025-3-24 02:06 作者: FLOAT 時(shí)間: 2025-3-24 06:07 作者: aviator 時(shí)間: 2025-3-24 08:49 作者: 索賠 時(shí)間: 2025-3-24 11:25 作者: 貴族 時(shí)間: 2025-3-24 15:40
https://doi.org/10.1007/978-3-319-39708-5acute lymphoblastic leukemia; pediatrics; hematology; genetics; cytogenetics; immunotherapy; first-line tr作者: SAGE 時(shí)間: 2025-3-24 21:59
978-3-319-81947-1Springer International Publishing Switzerland 2017作者: 遠(yuǎn)地點(diǎn) 時(shí)間: 2025-3-25 00:56 作者: 加劇 時(shí)間: 2025-3-25 05:57 作者: Sigmoidoscopy 時(shí)間: 2025-3-25 09:28
Cellular Therapy,ul attention to CAR T cell manufacturing processes, it may be possible for CAR T cell therapy to replace allogeneic transplantation in this disease setting. In this chapter, we review the science behind CAR T cell therapy, the data from published clinical studies in this field and finally consider h作者: IRS 時(shí)間: 2025-3-25 12:29 作者: 廣告 時(shí)間: 2025-3-25 19:43
resource poor countries are also discussed in detail...This is an indispensable guide for ?research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood?leukemia..978-3-319-81947-1978-3-319-39708-5作者: 彎曲道理 時(shí)間: 2025-3-25 22:32 作者: forestry 時(shí)間: 2025-3-26 03:05
Filippo M. Denaro,Giuliano De Stefanobut standard flow cytometry often does not reliably detect MRD levels below 10., whereas ASO-PCR is time-consuming and labor intensive. Therefore two high throughput technologies are being explored; high throughput sequencing and next generation (multidimensional) flow cytometry, both evaluating mil作者: CHOKE 時(shí)間: 2025-3-26 07:36
Sebastian Willman,Phoebe A. Cohenul attention to CAR T cell manufacturing processes, it may be possible for CAR T cell therapy to replace allogeneic transplantation in this disease setting. In this chapter, we review the science behind CAR T cell therapy, the data from published clinical studies in this field and finally consider h作者: modish 時(shí)間: 2025-3-26 11:51 作者: Obstacle 時(shí)間: 2025-3-26 15:09
Diagnostic Flow Cytometry and Immunophenotypic Classification,esion molecules and can be widely expressed or restricted to a specific stage of maturation/activation of a defined lineage. Thus, patterns of CD antigen expression can identify the lineage, maturation and functional stages of cells and are invaluable for evaluating normal haemopoiesis and the malignant state, including ALL.作者: 偏狂癥 時(shí)間: 2025-3-26 17:21 作者: 美麗的寫 時(shí)間: 2025-3-26 22:49 作者: 清澈 時(shí)間: 2025-3-27 03:59 作者: 能量守恒 時(shí)間: 2025-3-27 06:59
Katherine N. Marenco,David J. Bottjeras well as haematological malignancies. These immunotherapies e.g. in combination with standard of care might lead to better and more sustained remission rates. Furthermore the timing of administration of antibodies with or without standard of care might be a useful strategy for the therapy of the patients.作者: antedate 時(shí)間: 2025-3-27 11:14 作者: Toxoid-Vaccines 時(shí)間: 2025-3-27 14:37 作者: Lumbar-Stenosis 時(shí)間: 2025-3-27 19:34
Book 2017are. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are?utilized?to develop new prognostic stratification systems and target therapy...Readers will learn about current treatment and outcomes, such as immunoth作者: Antagonism 時(shí)間: 2025-3-28 01:07
https://doi.org/10.1007/978-90-481-8704-1esion molecules and can be widely expressed or restricted to a specific stage of maturation/activation of a defined lineage. Thus, patterns of CD antigen expression can identify the lineage, maturation and functional stages of cells and are invaluable for evaluating normal haemopoiesis and the malignant state, including ALL.作者: 6Applepolish 時(shí)間: 2025-3-28 03:47 作者: 暗諷 時(shí)間: 2025-3-28 09:41
ns with state of the art knowledge to guide their research a.This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusse作者: Breach 時(shí)間: 2025-3-28 13:27 作者: Exaggerate 時(shí)間: 2025-3-28 15:23
https://doi.org/10.1007/978-94-007-2339-9s in low middle income countries (LMIC) over the last 50 years. This inequity is all the more unfortunate because cALL is curable with cheap generic drugs using an appropriately designed treatment protocol, good diagnostic and supportive care, and socio-economic support for the family. Even in the most deprived settings, 30% of cALL can be cured.作者: facetious 時(shí)間: 2025-3-28 18:48 作者: 思想 時(shí)間: 2025-3-29 02:32
Developing World Perspective,s in low middle income countries (LMIC) over the last 50 years. This inequity is all the more unfortunate because cALL is curable with cheap generic drugs using an appropriately designed treatment protocol, good diagnostic and supportive care, and socio-economic support for the family. Even in the most deprived settings, 30% of cALL can be cured.作者: Militia 時(shí)間: 2025-3-29 06:36
Amelinda E. Webb,Lindsey R. Leightonw relapses. In T-ALL patients with bone marrow relapse, little progress has been made over the last three decades. A better understanding of the biology of disease recurrence, targeted therapy and innovative approaches to allografts offers possible ways of improving outcomes in the coming decades.作者: 換話題 時(shí)間: 2025-3-29 10:29
Relapsed Acute Lymphoblastic Leukemia of Childhood,w relapses. In T-ALL patients with bone marrow relapse, little progress has been made over the last three decades. A better understanding of the biology of disease recurrence, targeted therapy and innovative approaches to allografts offers possible ways of improving outcomes in the coming decades.作者: flaunt 時(shí)間: 2025-3-29 15:13
Epidemiology and Etiology of Childhood ALL,hood ALL arises from in utero chromosomal abnormalities that can lead to clonal expansion of pre-leukemic precursor cells. The risk factors for ALL in children are multiple, most notably common germline polymorphisms and rare genetic syndromes that directly influence hematopoiesis and cell cycling, 作者: HERTZ 時(shí)間: 2025-3-29 17:21
Clinical Presentation and Prognostic Factors,ave a more varied presentation. Bone pain and the signs and symptoms of mediastinal and central nervous system involvement are of particular relevance. Time to presentation for medical attention is related to presenting symptoms. In this chapter, the clinical and laboratory features of ALL at presen作者: 罐里有戒指 時(shí)間: 2025-3-29 19:59 作者: 努力趕上 時(shí)間: 2025-3-29 23:53 作者: Ordeal 時(shí)間: 2025-3-30 04:47
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Antileukemic Drugs,ple effector mechanisms of the antileukemic agents that are responsible for the efficacy (Fig. 5.1 and Table 5.1). This contrasts the modern era of targeted therapy, where molecular mapping of chemoresistant cancer cells has led to development of drugs that specifically target aberrant pathways (see作者: detach 時(shí)間: 2025-3-30 09:53
Minimal Residual Disease (MRD) Diagnostics: Methodology and Prognostic Significance,. MRD measurements have proven to be the strongest independent prognostic factor, allowing for risk-group assignment into different treatment arms, ranging from treatment reduction or intensification. MRD measurements are also guiding treatment decisions in relapsed ALL patients and patients undergo作者: Ostrich 時(shí)間: 2025-3-30 13:42
First Line Treatment: Current Approach,l progress on several fronts in the treatment of childhood lymphoblastic leukaemia (ALL). Reductions in relapse risk realised during that period have unmasked the morbidity and mortality associated with intensive therapy and revealed late treatment-related side effects. As a result, attention has fo作者: 踉蹌 時(shí)間: 2025-3-30 17:19 作者: Itinerant 時(shí)間: 2025-3-30 20:43 作者: 調(diào)味品 時(shí)間: 2025-3-31 04:25
